306 related articles for article (PubMed ID: 33672357)
1. KRAS
Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in
da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120
[TBL] [Abstract][Full Text] [Related]
3. Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer.
Nardi F; Perurena N; Schade AE; Li ZH; Ngo K; Ivanova EV; Saldanha A; Li C; Gokhale PC; Hata AN; Barbie DA; Paweletz CP; Jänne PA; Cichowski K
J Clin Invest; 2023 Aug; 133(16):. PubMed ID: 37384411
[TBL] [Abstract][Full Text] [Related]
4. Ganoderma microsporum immunomodulatory protein combined with KRAS
Hua WJ; Hwang WL; Yeh H; Lin ZH; Hsu WH; Lin TY
Int J Biol Macromol; 2024 Feb; 259(Pt 2):129291. PubMed ID: 38211909
[TBL] [Abstract][Full Text] [Related]
5. YTHDF1 Promotes Cyclin B1 Translation through m
Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
[TBL] [Abstract][Full Text] [Related]
6. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
Molina-Arcas M; Moore C; Rana S; van Maldegem F; Mugarza E; Romero-Clavijo P; Herbert E; Horswell S; Li LS; Janes MR; Hancock DC; Downward J
Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534020
[TBL] [Abstract][Full Text] [Related]
7. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K
Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159
[TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation.
Xu L; Ding R; Song S; Liu J; Li J; Ju X; Ju B
J Gene Med; 2024 Jan; 26(1):e3658. PubMed ID: 38282149
[TBL] [Abstract][Full Text] [Related]
9. The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol.
Albayrak G; Korkmaz FD; Tozcu D; Dogan Turacli I
J Cell Biochem; 2019 Jun; 120(6):10564-10571. PubMed ID: 30628735
[TBL] [Abstract][Full Text] [Related]
10. A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition.
Barrios-Bernal P; Lucio-Lozada J; Ramos-Ramírez M; Hernández-Pedro N; Arrieta O
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901764
[TBL] [Abstract][Full Text] [Related]
11. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
[TBL] [Abstract][Full Text] [Related]
12. EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma.
Chalela R; González-García JG; Khilzi K; Curull V; Sánchez-Font A; Longarón R; Rodrigo-Calvo MT; Martín-Ontiyuelo C; Gea J; Bellosillo B
Pathol Oncol Res; 2021; 27():598292. PubMed ID: 34257550
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor of Differentiation-1 Sustains Mutant
Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
[TBL] [Abstract][Full Text] [Related]
14. IκB Kinase α Is Required for Development and Progression of
Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT
Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349
[TBL] [Abstract][Full Text] [Related]
15. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.
Hou X; Zhou C; Liang Z; Qiu H; Zhou Z; Zheng H; Li Z; Wang Y; Qi X; Lu L; Cao Y; Zheng J
Phytomedicine; 2023 Dec; 121():155093. PubMed ID: 37783131
[TBL] [Abstract][Full Text] [Related]
16. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
[TBL] [Abstract][Full Text] [Related]
17. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
18. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
19. Integrin-linked kinase (ILK) regulates KRAS, IPP complex and Ras suppressor-1 (RSU1) promoting lung adenocarcinoma progression and poor survival.
Nikou S; Arbi M; Dimitrakopoulos FD; Sirinian C; Chadla P; Pappa I; Ntaliarda G; Stathopoulos GT; Papadaki H; Zolota V; Lygerou Z; Kalofonos HP; Bravou V
J Mol Histol; 2020 Aug; 51(4):385-400. PubMed ID: 32592097
[TBL] [Abstract][Full Text] [Related]
20. The KRAS
Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
